Synthesis and cytotoxic studies of hydroximino derivatives of some 16E-arylidenosteroids

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 9, 2004, Pages 551-556

  Chattopadhaya, Raja ^a   Jindal, Dharam Paul ^a   Minu, Maninder ^a   Gupta, Ranju ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

16 Arylidenosteroids, antineoplastic activity, hydroximino derivatives, oximes and dioximes, synthesis; Antineoplastic agents

Indexed keywords

16 (3,4,5 TRIMETHOXYBENZYLIDENE) 17 OXIMINO 5 ANDROSTEN 3BETA YLACETATE; 16 BENZYLIDENE 17 OXIMINO 5 ANDROSTEN 3BETA YLACETATE; ALDEHYDE DERIVATIVE; CYTOTOXIC AGENT; PACLITAXEL; PRASTERONE; PRASTERONE ACETATE; STEROID; UNCLASSIFIED DRUG;

ALDOL REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; EXPERIMENTAL NEOPLASM; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

EID: 4644254277     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297011     Document Type: Article

References (28)

1. Tomera, J. F., Breast cancer: In search of a cure. Drugs of Today 30, 565 (1994)
2. Howell, A., Dowsett, M., Recent advances in endocrine therapy of breast cancer. Br. Med. J. 315, 863 (1997)
3. Buzdar, A., Howell, A., Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin. Cancer Res. 7, 2620 (2001)
4. Njar, V. C. O., Brodie, A. M. H., Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 58, 233 (1999)
5. Seralini, G-E., Moslemi, S., Aromatase inhibitors: Past, present and future. Mol. Cell. Endocrinol. 178, 117 (2001)
6. O'Reilly, J. M., Brueggemeier, R. W., Development of steroidal and nonsteroidal inhibitors of aromatase for the treatment of hormone-dependent breast cancer. Curr. Med. Chem. 3, 11 (1996)
7. Brodie, A. M. H., Njar, V. C. O., Aromatase inhibitors and their application in breast cancer treatments. Steroids 65, 171 (2000)
8. Recanatini, M., Bisi, A., Cavalli, A. et al., A new class of nonsteroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17α-hydroxylase/C17,20- lyase. J. Med. Chem. 44, 672 (2001)
9. Bhatnagar, A. S., Brodie, A. M. H., Long, B. J. et al., Intracellulararomatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 76, 199 (2001)
10. Sasano, H., Harada, N., Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev. 19, 593 (1998)
11. Cole, P. A., Robinson, C. H., Mechanism and inhibition of cytochrome P-450 aromatase. J. Med. Chem. 33, 2933 (1990)
12. Hartmann, R. W., Bayer, H., Grun, G., Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indanes, and tetralins. J. Med. Chem. 37, 1275 (1994)
13. Bayer, H., Hartmann, R. W., Pyridyl-substituted tetralone derivatives: a new class of nonsteroidal aromatase inhibitors. Arch. Pharm. (Weinheim) 324, 815 (1991)
14. Numazawa, M., Osawa, Y., Synthesis of 16a-bromoacetoxy androgens and 17β-bromoacetylamino-4-androsten-3-one: Potential affinity labels of human placental aromatase. Steroids 38, 149 (1981)
15. Christiansen, R. G., Clinton, R. O., Greenbush, E. et al., U.S. 3,163,641. 16-Substituted androstanes and androstenes. Chem. Abstr. 62, 7834 (1965)
16. Deive, N., Rodriguez, J., Jimenez, C., Synthesis of cytotoxic 6E-hydroximino-4-ene steroids: Structure/activity studies. J. Med. Chem. 44, 2612 (2001)
17. Rodriguez, J., Nunez, L., Peixinho, S. et al., Isolation and synthesis of the first natural 6-hydroximino-4-en-3one steroids from the sponges Cinachyrella spp. Tetrahedron Lett. 38, 1833 (1997)
18. Holland, H. L., Kumaresan, S., Tan, L. et al., Synthesis of new 6-hydrox imino-oxo steroids, A new class of aromatase inhibitor. J. Chem. Soc. Perkin Trans. 1, 585 (1992)
19. Sam, J., Alwani, D. W., Aparajithan, K., Reduction products of 2-pyridylmethylene-1-indanones. J. Heterocyc. Chem. 2, 366 (1965).
20. Thamotharan, S., Parthasarathi, V., Gupta, R. et al., 16-[3-Methoxy-4-(2-piperidin-1-ylethoxy)benzylidene]-17-oxo-5-androsten-3β- yl acetate monohydrate. Acta Cryst. C58, o727 (2002)
21. Vasuki, G., Parthasarathi, V., Ramammurthi, K. et al., 16-(3-Pyridylmethylene)androst-4-ene-3,17-dione. Acta Cryst. E58, o1359 (2002)
22. Vasuki, G., Parthasarathi, V., Ramammurthi, K. et al., 17-Oxo-16-(2-yridylmethylene)androst-5-en-3β-ol monohydrate. Acta Cryst. C57, o1062 (2001)
23. Hershberg, E. B., Regeneration of steroid ketones from their semicarbazones with pyruvic acid. J. Org. Chem. 13, 542 (1948)
24. Glazier, E. R., Bromination of 17-oxo steroids with cupric bromide. J. Org. Chem. 27, 2937 (1962)
25. Alley, M. C., Scudiero, D. A., Monks, P. A. et al., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589 (1988)
26. Grever, M. R., Schepartz, S. A., Chabner, B. A., The national cancer institute: Cancer drug discovery and development program. Semin. Oncol. 19, 622 (1992)
27. Boyd, M. R., Paull, K. D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34, 91 (1995)
28. Hellingshead, M., Alley, M. C., Camalier, R. F. et al., In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57, 131 (1995)